Free tool
FAERS Monitor: Impoyz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209483 or its brand name (Impoyz, Clobetasol Propionate). Reports on generic versions are filed under their own applications.
Reports
10,709
Serious
4,983
47% of reports
Hospitalization
2,062
Death reported
441
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,119
- pruritus990
- off label use687
- rash686
- product use in unapproved indication559
- psoriasis555
- fatigue536
- headache503
- diarrhoea450
- nausea445
- dry skin426
- arthralgia422
- pain408
- skin exfoliation404
- erythema344
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 20 |
| 2006 | 58 |
| 2007 | 92 |
| 2008 | 95 |
| 2009 | 125 |
| 2010 | 135 |
| 2011 | 215 |
| 2012 | 318 |
| 2013 | 162 |
| 2014 | 185 |
| 2015 | 346 |
| 2016 | 403 |
| 2017 | 536 |
| 2018 | 464 |
| 2019 | 477 |
| 2020 | 560 |
| 2021 | 608 |
| 2022 | 926 |
| 2023 | 1,254 |
| 2024 | 1,175 |
| 2025 | 1,342 |
| 2026 | 1,196 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,450 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin exfoliationSignal | 404 | 9.4 | 8.6 | 3,040 |
| psoriasisSignal | 555 | 8.4 | 7.7 | 3,605 |
| dry skinSignal | 426 | 6.3 | 5.7 | 1,894 |
| pruritusSignal | 990 | 5.1 | 4.8 | 3,282 |
| product use in unapproved indicationSignal | 559 | 4.4 | 4.1 | 1,499 |
| erythemaSignal | 344 | 3.3 | 3.0 | 551 |
| rashSignal | 686 | 3.1 | 2.9 | 989 |
| arthralgia | 422 | 2.0 | 1.8 | 212 |
| drug ineffective | 1,119 | 1.7 | 1.6 | 319 |
| headache | 503 | 1.6 | 1.4 | 109 |
| off label use | 687 | 1.5 | 1.4 | 136 |
| diarrhoea | 450 | 1.4 | 1.3 | 46 |
| fatigue | 536 | 1.4 | 1.2 | 51 |
| pain | 408 | 1.3 | 1.2 | 30 |
| nausea | 445 | 1.1 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.